| 1. |
牛雪陽, 張月華. 發育性癲癇性腦病研究進展. 精準醫學雜志, 2024, 39(6): 476-481.
|
| 2. |
黨洋斌, 梁宇欣, 王天成. 進行性肌陣攣癲癇相關治療的研究進展. 中國臨床藥理學與治療學, 2023, 28(10): 1184-1194.
|
| 3. |
Zheng Y, Chen J. Voltage-gated potassium channels and genetic epilepsy. Front Neurol, 2024, 15: 1466075.
|
| 4. |
Li X, Zheng Y, Li S, et al. Kv3. 1 channelopathy: a novel loss-of-function variant and the mechanistic basis of its clinical phenotypes. Ann Transl Med, 2021, 9: 1397.
|
| 5. |
Cameron JM, Maljevic S, Nair U, et al. Encephalopathies with KCNC1 variants: genotype-phenotype-functional correlations. Ann Clin Transl Neurol, 2019, 6: 1263-1272.
|
| 6. |
Kim H, Lee S, Choi M, et al. Familial cases of progressive myoclonic epilepsy caused by maternal somatic mosaicism of a recurrent KCNC1 p. Arg320His mutation [J]. Brain Dev, 2018, 40 (5): 429-432.
|
| 7. |
Lima GSB, Nobrega PL, Freua F, et al. Myoclonus improvement after seizures in progressive myoclonic epilepsy type 7: a case report. BMC Neurol, 2024, 24(1): 169.
|
| 8. |
Muona M, Berkovic SF, Dibbens LM, et al. A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy. Nat Genet, 2015, 47(1): 39-46.
|
| 9. |
張靜, 張月華, 陳嬌陽, 等. KCNC1 基因突變導致的進行性肌陣攣癲癇 3 例及文獻復習. 中華實用兒科臨床雜志, 2019, 34(24): 1876-1881.
|
| 10. |
Ferlazzo E, Trenite DKN, de Haan GJ, et al. Update on Pharmacological Treatment of Progressive Myoclonus Epilepsies. Curr Pharm Des, 2017, 23(37): 5662-5666.
|
